ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP 株式レポート

時価総額:US$1.1b

ANI Pharmaceuticals マネジメント

マネジメント 基準チェック /24

ANI Pharmaceuticalsの CEO はNikhil Lalwaniで、 Sep2020年に任命され、 の在任期間は 4.17年です。 の年間総報酬は$ 8.08Mで、 9.5%給与と90.5%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.91%を直接所有しており、その価値は$ 21.63M 。経営陣と取締役会の平均在任期間はそれぞれ3年と4.2年です。

主要情報

Nikhil Lalwani

最高経営責任者

US$8.1m

報酬総額

CEO給与比率9.5%
CEO在任期間4.2yrs
CEOの所有権1.9%
経営陣の平均在職期間3yrs
取締役会の平均在任期間4.2yrs

経営陣の近況

Recent updates

Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

Nov 02

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28
We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

CEO報酬分析

ANI Pharmaceuticals の収益と比較して、Nikhil Lalwani の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$31m

Dec 31 2023US$8mUS$764k

US$15m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$5mUS$737k

-US$50m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$7mUS$715k

-US$43m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$4mUS$199k

-US$23m

報酬と市場: Nikhilの 総報酬 ($USD 8.08M ) は、 US市場 ($USD 3.15M ) の同規模の企業の平均を上回っています。

報酬と収益: Nikhilの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Nikhil Lalwani (46 yo)

4.2yrs

在職期間

US$8,078,353

報酬

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.6m
Stephen Carey
Senior VP of Finance & CFO8.5yrsUS$2.58m0.83%
$ 9.4m
Chad Gassert
Senior Vice President of Corporate Development & Strategy3yrsUS$1.90m1.24%
$ 14.1m
Christopher Mutz
Senior Vp & Head of Rare Disease3.8yrsUS$1.91m0.39%
$ 4.4m
Ori Gutwerg
Senior Vice President of Generics3.8yrsUS$1.94m0.40%
$ 4.5m
Muthusamy Shanmugam
Head of R&D3yrsデータなし0.26%
$ 3.0m
James Marken
Senior Vice President of Operations8.5yrsUS$1.43m0.60%
$ 6.8m
Elizabeth Powell
Chief Compliance Officer & Head of Legal of Rare Disease2.8yrsデータなしデータなし
Meredith Cook
Senior VP2.3yrsデータなし0.29%
$ 3.3m
Krista Davis
Senior VP & Chief Human Resources Officer2.2yrsデータなし0.26%
$ 2.9m
Mary Pao
Chief Medical Officer2.8yrsデータなしデータなし
Thomas Rowland
Senior VP & Head of Established Brands3yrsデータなし0.17%
$ 1.9m

3.0yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: ANIPの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.6m
Muthusamy Shanmugam
Head of R&D3yrsデータなし0.26%
$ 3.0m
Patrick Walsh
Independent Chairman6.5yrsUS$422.21k0.38%
$ 4.3m
Antonio Pera
Independent Director4.3yrsUS$393.25k0.16%
$ 1.8m
Thomas Haughey
Independent Director6.5yrsUS$412.21k0.26%
$ 3.0m
Jeanne Thoma
Independent Director4.3yrsUS$395.75k0.21%
$ 2.3m
Renee Tannenbaum
Independent Director2.7yrsUS$392.37k0.12%
$ 1.3m
Matthew Leonard
Independent Director1.3yrsUS$470.76k0.061%
$ 693.9k

4.2yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: ANIPの 取締役会経験豊富 であると考えられます ( 4.2年の平均在任期間)。